Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

WIN Symposium 2018 /
Precision medicine in newly diagnosed breast cancer

25th - 26th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.07.18
Views: 1185

Dr Laura Esserman - UCSF Carol Franc Buck Breast Care Center, San Francisco, USA

Dr Esserman speaks with ecancer at the 2018 WIN symposium about identifying best care procedures for breast cancer patients using precision techniques.

She outlines the changing understanding of breast cancer, from one disease to a whole disease area, and of breast cancer patients in terms of their treatment suitability and progression risk.

Dr Esserman was one of the authors of a paper that used molecular testing to identify breast cancer patients at the lowest risk of death, published in JAMA Oncology last June, and highlights how identifying and treating early disease appropriately can offer the most impact for patients, and the best course of action for healthcare systems.

Dr Esserman introduces the WISDOM trial, currently recruiting patients, and a refined iteration of the iSPY trial as two cases of precision oncology for breast cancer, and discusses the TAILORx study presented at ASCO 2018.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation